Phase II Study of Combined Targeted p53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel for Treatment of Metastatic Pancreatic Cancer
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of SGT-53 given in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer.
General Information
NCT#: NCT02340117
Study ID: SGT53-02-1
Trial Phase: Phase II
Trial Sponsor: SynerGene Therapeutics, Inc.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, SGT-53